8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Apr 27, 2026·SEC
Sagimet Biosciences Inc.(SGMT)Earnings, Financials & Key Ratios
SGMT•NASDAQ
Price updated Jun 19, 2026
AboutSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.Show more
- Revenue$0
- EBITDA-$57M-24.8%
- Net Income-$51M-12.0%
- EPS (Diluted)-1.58-9.0%
- ROE-38.2%-3.5%
SGMT Key Insights
Sagimet Biosciences Inc. (SGMT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 35.0% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SGMT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SGMT Price & Volume
Sagimet Biosciences Inc. (SGMT) stock price & volume — 10-year historical chart
Loading chart...
SGMT Growth Metrics
Sagimet Biosciences Inc. (SGMT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM23.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM23.3%
Return on Capital
10 Years-62.32%
5 Years-50.09%
3 Years-46.15%
Last Year-42.58%
SGMT Recent Earnings
Sagimet Biosciences Inc. (SGMT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.33+15.4%
$0.39
Rev
—
—
Q2 2026
Mar 11, 2026Metric
Actual
Est
EPS
$0.29+32.6%
$0.43
Rev
—
$1M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.40+2.4%
$0.41
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.32+38.5%
$0.52
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.33vs $0.39+15.4% | — |
| Q2 2026 | Mar 11, 2026 | $0.29vs $0.43+32.6% | —vs $1M |
| Q4 2025 | Nov 13, 2025 | $0.40vs $0.41+2.4% | — |
| Q3 2025 | Aug 13, 2025 | $0.32vs $0.52+38.5% | — |
Based on last 12 quarters of dataView full earnings history →
SGMT Peer Comparison
Sagimet Biosciences Inc. (SGMT) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MDGL | 11.66B | 505.75 | -39.36 | 432.05% | -27.32% | -50.15% | 0.59 | |
 AKBA | 287.04M | 1.07 | -51.44 | 47.46% | -8.83% | -62.72% | 6.63 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 GNFT | 447.53M | 8.95 | 256.88 | 134.56% | -14.12% | -22.98% | 0.90 | |
 HIMS | 7.79B | 35.47 | 69.55 | 59% | -0.56% | -2.48% | 2.34 | |
 ALDX | 118.23M | 1.96 | -3.50 | -0% | 0.35 | |||
 CRL | 8.91B | 185.00 | -63.57 | -0.85% | -4.59% | -5.66% | 0.95 |
Compare SGMT vs Peers
Sagimet Biosciences Inc. (SGMT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SGMT Income Statement
Sagimet Biosciences Inc. (SGMT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 2M | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | -100% | - | - |
Cost of Goods Sold | 88K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | -88K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 2M▲ 0% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | 100% | - | - | - |
Gross Profit Growth % | - | 100% | - | - | - | -100% | - | - |
Operating Expenses | 14.07M | 11.4M | 23.72M | 31.05M | 32.74M | 54.45M | 56.89M | 48.74M |
OpEx % of Revenue | - | - | - | - | 1637% | - | - | - |
Selling, General & Admin | 5.68M | 3.22M | 4.38M | 6.14M | 12.96M | 16.01M | 17.84M | 18.03M |
SG&A % of Revenue | - | - | - | - | 648.15% | - | - | - |
Research & Development | 8.39M | 8.18M | 19.34M | 24.92M | 19.78M | 38.44M | 39.05M | 30.71M |
R&D % of Revenue | - | - | - | - | 988.85% | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -14.16M▲ 0% | -11.4M▲ 19.5% | -23.72M▼ 108.1% | -31.05M▼ 30.9% | -30.74M▲ 1.0% | -54.45M▼ 77.1% | -56.89M▼ 4.5% | -48.74M▲ 0% |
Operating Margin % | - | - | - | - | -1537% | - | - | - |
Operating Income Growth % | - | 19.49% | -108.06% | -30.93% | 1.01% | -77.14% | -4.47% | - |
EBITDA | -14.07M | -11.4M | -23.72M | -31.05M | -30.74M | -45.57M | -56.89M | -48.74M |
EBITDA Margin % | - | - | - | - | -1537% | - | - | - |
EBITDA Growth % | - | 18.99% | -108.08% | -30.93% | 1.01% | -48.23% | -24.85% | 23.32% |
D&A (Non-Cash Add-back) | 88K | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
EBIT | -14.2M | -11.4M | -23.72M | -31.05M | -30.74M | -45.57M | -56.89M | -48.74M |
Net Interest Income | 64K | 30K | 26K | 553K | 2.86M | 0 | 0 | -1.69M |
Interest Income | 128K | 30K | 26K | 553K | 2.86M | 0 | 0 | -1.69M |
Interest Expense | 64K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -102K | 30K | -723K | 556K | 2.86M | 8.89M | 5.85M | 5.22M |
Pretax Income | -14.26M▲ 0% | -11.37M▲ 20.3% | -24.44M▼ 115.0% | -30.5M▼ 24.8% | -27.88M▲ 8.6% | -45.57M▼ 63.5% | -51.04M▼ 12.0% | -43.51M▲ 0% |
Pretax Margin % | - | - | - | - | -1393.8% | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -14.26M▲ 0% | -11.37M▲ 20.3% | -24.44M▼ 115.0% | -30.5M▼ 24.8% | -27.88M▲ 8.6% | -45.57M▼ 63.5% | -51.04M▼ 12.0% | -43.51M▲ 0% |
Net Margin % | - | - | - | - | -1393.8% | - | - | - |
Net Income Growth % | - | 20.27% | -114.97% | -24.78% | 8.6% | -63.46% | -12.01% | 23.82% |
Net Income (Continuing) | -14.26M | -11.37M | -24.44M | -30.5M | -27.88M | -45.57M | -51.04M | -43.51M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.64▲ 0% | -0.51▲ 20.3% | -1.10▼ 115.7% | -1.38▼ 25.5% | -1.53▼ 10.9% | -1.45▲ 5.2% | -1.58▼ 9.0% | -1.34▲ 0% |
EPS Growth % | - | 20.31% | -115.69% | -25.45% | -10.87% | 5.23% | -8.97% | 23.3% |
EPS (Basic) | -0.64 | -0.51 | -1.10 | -1.38 | -1.53 | -1.45 | -1.58 | - |
Diluted Shares Outstanding | 22.17M | 22.17M | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M | 32.56M |
Basic Shares Outstanding | 22.17M | 22.17M | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M | 32.56M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
SGMT Balance Sheet
Sagimet Biosciences Inc. (SGMT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 10.81M | 68.74M | 58.66M | 32.79M | 96.65M | 152.77M | 116.4M | 107.72M |
Cash & Short-Term Investments | 10.21M | 68.7M | 56.73M | 32.34M | 94.9M | 151.25M | 113.12M | 104.54M |
Cash Only | 10.21M | 68.7M | 56.73M | 158K | 75.14M | 75.84M | 35.02M | 36.63M |
Short-Term Investments | 0 | 0 | 0 | 32.19M | 19.76M | 75.41M | 78.1M | 67.91M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 58K | 36K | 1.51M | 34K | 397K | 463K | 3.28M | 3.18M |
Total Non-Current Assets | 345K | 221K | 369K | 239K | 73K | 7.49M | 78K | 39K |
Property, Plant & Equipment | 318K | 194K | 342K | 212K | 73K | 77K | 78K | 39K |
Fixed Asset Turnover | - | - | - | - | 27.40x | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 7.41M | 0 | 18.86M |
Other Non-Current Assets | 27K | 27K | 27K | 27K | 0 | 0 | 0 | 0 |
Total Assets | 11.16M▲ 0% | 68.96M▲ 517.9% | 59.03M▼ 14.4% | 33.03M▼ 44.0% | 96.72M▲ 192.8% | 160.26M▲ 65.7% | 116.48M▼ 27.3% | 107.75M▲ 0% |
Asset Turnover | - | - | - | - | 0.02x | - | - | 0.00x |
Asset Growth % | - | 517.91% | -14.4% | -44.05% | 192.81% | 65.7% | -27.32% | -107.44% |
Total Current Liabilities | 2.08M | 1.91M | 2.44M | 5.28M | 5.65M | 4.45M | 5.1M | 5.3M |
Accounts Payable | 1.2M | 513K | 761K | 1.13M | 186K | 1.43M | 1.31M | 2.3M |
Days Payables Outstanding | 4.97K | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 78K | 39K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 243K | 185K | 57K | 556K | 5K | 3.71M | 2.96M |
Current Ratio | 5.21x | 35.99x | 24.04x | 6.21x | 17.09x | 34.30x | 22.82x | 20.34x |
Quick Ratio | 5.21x | 35.99x | 24.04x | 6.21x | 17.09x | 34.30x | 22.82x | 20.34x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 134.4M | 202.96M | 214.85M | 214.7M | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 211K | 65K | 224K | 78K | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 134.19M | 202.89M | 214.63M | 214.62M | 0 | 0 | 0 | 0 |
Total Liabilities | 136.47M | 204.87M | 217.29M | 219.98M | 5.65M | 4.45M | 5.1M | 5.3M |
Total Debt | 341K | 210K | 348K | 211K | 65K | 78K | 78K | 39K |
Net Debt | -9.87M | -68.49M | -56.38M | 53K | -75.07M | -75.76M | -34.94M | -36.59M |
Debt / Equity | - | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.75x |
Interest Coverage | -221.83x | - | - | - | - | - | - | - |
Total Equity | -125.31M▲ 0% | -135.91M▼ 8.5% | -158.26M▼ 16.4% | -186.95M▼ 18.1% | 91.06M▲ 148.7% | 155.81M▲ 71.1% | 111.38M▼ 28.5% | 102.46M▲ 0% |
Equity Growth % | - | -8.45% | -16.44% | -18.13% | 148.71% | 71.09% | -28.51% | -113.92% |
Book Value per Share | -5.65 | -6.13 | -7.14 | -8.43 | 5.01 | 4.97 | 3.44 | 3.15 |
Total Shareholders' Equity | -125.31M | -135.91M | -158.26M | -186.95M | 91.06M | 155.81M | 111.38M | 102.46M |
Common Stock | 1K | 1K | 1K | 1K | 2K | 3K | 3K | 3K |
Retained Earnings | -155.56M | -166.93M | -191.37M | -221.87M | -249.74M | -295.31M | -346.35M | -357M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | -84K | 30K | 230K | 120K | 8K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SGMT Cash Flow Statement
Sagimet Biosciences Inc. (SGMT) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -10.55M | -10.42M | -21.71M | -24.49M | -23.77M | -42.44M | -45.65M | -39.73M |
Operating CF Margin % | - | - | - | - | -1188.3% | - | - | - |
Operating CF Growth % | - | 1.29% | -108.43% | -12.81% | 2.96% | -78.55% | -7.58% | 19.86% |
Net Income | -14.26M | -11.37M | -24.44M | -30.5M | -27.88M | -45.57M | -51.04M | -43.51M |
Depreciation & Amortization | 1K | 0 | 0 | 130K | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 2.99M | 775K | 1.9M | 1.88M | 4.99M | 5.29M | 6.45M | 4.98M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 75K | 104K | 883K | -215K | 98K | -1.11M | -8K | 2.23M |
Working Capital Changes | 645K | 75K | -55K | 4.21M | -978K | -1.05M | -1.05M | -3.42M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 120K | -907K | 929K | 0 |
Cash from Investing | -27K | 20K | 0 | -32.01M | 12.58M | -61.68M | 4.56M | 11.36M |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | -27K | 20K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 18.48M | 68.89M | 9.74M | -73K | 86.17M | 104.82M | 275K | 275K |
Debt Issued (Net) | -3.36M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 21.85M | 68.89M | 10.8M | 12K | 89.68M | 105.75M | 275K | 275K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -1.06M | -85K | -3.51M | -931K | 0 | 0 |
Net Change in Cash | 7.91M▲ 0% | 58.49M▲ 639.8% | -11.97M▼ 120.5% | -56.57M▼ 372.6% | 74.98M▲ 232.5% | 701K▼ 99.1% | -40.82M▼ 5923.0% | -28.09M▲ 0% |
Free Cash Flow | -10.55M▲ 0% | -10.42M▲ 1.3% | -21.71M▼ 108.4% | -24.49M▼ 12.8% | -23.77M▲ 3.0% | -42.44M▼ 78.6% | -45.65M▼ 7.6% | -39.73M▲ 0% |
FCF Margin % | - | - | - | - | -1188.3% | - | - | - |
FCF Growth % | - | 1.29% | -108.43% | -12.81% | 2.96% | -78.55% | -7.58% | 21.74% |
FCF per Share | -0.48 | -0.47 | -0.98 | -1.10 | -1.31 | -1.35 | -1.41 | -1.22 |
FCF Conversion (FCF/Net Income) | 0.74x | 0.92x | 0.89x | 0.80x | 0.85x | 0.93x | 0.89x | 0.91x |
Interest Paid | 136K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SGMT Key Ratios
Sagimet Biosciences Inc. (SGMT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | -30.61% | -36.92% | -38.2% | -37.57% |
Return on Invested Capital (ROIC) | - | - | - | - | -85.05% | -54.53% | -46.1% |
Gross Margin | - | - | - | 100% | - | - | - |
Net Margin | - | - | - | -1393.8% | - | - | - |
Debt / Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x |
FCF Conversion | 0.92x | 0.89x | 0.80x | 0.85x | 0.93x | 0.89x | 0.91x |
Revenue Growth | - | - | - | - | -100% | - | - |
Related:SGMT Dividend History·SGMT Revenue History·SGMT Price History·SGMT P/E History·SGMT Financial Ratios·SGMT Institutional Holders
SGMT SEC Filings & Documents
Sagimet Biosciences Inc. (SGMT) SEC filings — annual & quarterly reports (10-K, 10-Q)
SGMT Frequently Asked Questions
Sagimet Biosciences Inc. (SGMT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Sagimet Biosciences Inc. (SGMT) grew revenue by 0.0% over the past year. Growth has been modest.
Sagimet Biosciences Inc. (SGMT) reported a net loss of $43.5M for fiscal year 2025.
Dividend & Returns
Sagimet Biosciences Inc. (SGMT) has a return on equity (ROE) of -38.2%. Negative ROE indicates the company is unprofitable.
Sagimet Biosciences Inc. (SGMT) had negative free cash flow of $39.7M in fiscal year 2025, likely due to heavy capital investments.